StockData

Lycia Therapeutics, Inc. (LYCA) stock analysis

LYCANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.35+0.43 (+1.39%)

Close on Nov 18, 2026Market cap –P/E –Yield –

Analysis

Not enough annual history yet

Analysis needs at least two fiscal years of reported financials for Lycia Therapeutics.

See a number that looks wrong?